LIMN
Price
$1.57
Change
-$0.15 (-8.67%)
Updated
Oct 7, 04:59 PM (EDT)
Capitalization
N/A
LYEL
Price
$17.56
Change
-$0.29 (-1.62%)
Updated
Oct 7, 04:59 PM (EDT)
Capitalization
342.92M
Interact to see
Advertisement

LIMN vs LYEL

Header iconLIMN vs LYEL Comparison
Open Charts LIMN vs LYELBanner chart's image
Liminatus Pharma
Price$1.57
Change-$0.15 (-8.67%)
Volume$1.45K
CapitalizationN/A
Lyell Immunopharma
Price$17.56
Change-$0.29 (-1.62%)
Volume$721
Capitalization342.92M
LIMN vs LYEL Comparison Chart in %
LIMN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LYEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
LIMN vs. LYEL commentary
Oct 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LIMN is a Buy and LYEL is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 08, 2025
Stock price -- (LIMN: $1.73 vs. LYEL: $17.85)
Brand notoriety: LIMN and LYEL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LIMN: 24% vs. LYEL: 79%
Market capitalization -- LIMN: $0 vs. LYEL: $342.92M
LIMN [@Biotechnology] is valued at $0. LYEL’s [@Biotechnology] market capitalization is $342.92M. The market cap for tickers in the [@Biotechnology] industry ranges from $103.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.05B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LIMN’s FA Score shows that 1 FA rating(s) are green whileLYEL’s FA Score has 0 green FA rating(s).

  • LIMN’s FA Score: 1 green, 4 red.
  • LYEL’s FA Score: 0 green, 5 red.
According to our system of comparison, both LIMN and LYEL are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LIMN’s TA Score shows that 4 TA indicator(s) are bullish while LYEL’s TA Score has 5 bullish TA indicator(s).

  • LIMN’s TA Score: 4 bullish, 3 bearish.
  • LYEL’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, LYEL is a better buy in the short-term than LIMN.

Price Growth

LIMN (@Biotechnology) experienced а +3.59% price change this week, while LYEL (@Biotechnology) price change was +19.24% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.94%. For the same industry, the average monthly price growth was +16.24%, and the average quarterly price growth was +90.12%.

Industries' Descriptions

@Biotechnology (+7.94% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LYEL YTD gains are higher at: 39.453 vs. LIMN (-84.581).
LIMNLYELLIMN / LYEL
CapitalizationN/A343M-
EBITDAN/A-199.95M-
Gain YTD-84.58139.453-214%
P/E RatioN/AN/A-
RevenueN/A60K-
Total CashN/A277M-
Total DebtN/A46.6M-
TECHNICAL ANALYSIS
Technical Analysis
LIMNLYEL
RSI
ODDS (%)
Bullish Trend 2 days ago
43%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
11%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
35%
Bullish Trend 2 days ago
85%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
77%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
25%
Bullish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
27%
Bullish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 6 days ago
42%
Bullish Trend 2 days ago
83%
Declines
ODDS (%)
Bearish Trend 19 days ago
33%
N/A
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
30%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
30%
Bullish Trend 2 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
LIMN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LYEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MHVYF27.662.41
+9.54%
Mitsubishi Heavy Industries Ltd.
DNPLY8.870.38
+4.48%
Dai Nippon Printing Co. Ltd.
BKUT500.00N/A
N/A
Bank of Utica (NY)
ZNNGY3.11N/A
N/A
Zhongyuan Bk Co Ltd
EGPLF0.12N/A
-1.08%
Eagle Plains Resources Ltd.

LIMN and

Correlation & Price change

A.I.dvisor tells us that LIMN and AIM have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LIMN and AIM's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LIMN
1D Price
Change %
LIMN100%
N/A
AIM - LIMN
29%
Poorly correlated
+1.52%
SGMT - LIMN
27%
Poorly correlated
+0.27%
LYEL - LIMN
23%
Poorly correlated
+0.56%
BGMSP - LIMN
23%
Poorly correlated
N/A
ALT - LIMN
22%
Poorly correlated
+2.56%
More

LYEL and

Correlation & Price change

A.I.dvisor indicates that over the last year, LYEL has been loosely correlated with VCYT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if LYEL jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LYEL
1D Price
Change %
LYEL100%
+0.56%
VCYT - LYEL
46%
Loosely correlated
+0.11%
CRBU - LYEL
39%
Loosely correlated
+3.08%
ERAS - LYEL
37%
Loosely correlated
-3.72%
TYRA - LYEL
36%
Loosely correlated
-1.68%
BEAM - LYEL
36%
Loosely correlated
+0.54%
More